Zeinab Faghfoori1, Rahebeh Shakerhosseini2, Lida Navai2, Mohammad Hossein Somi3, Zeinab Nikniaz1, Alireza Abadi4. 1. Students' Research Committee, Tabriz University of Medical Science, Tabriz, Iran. 2. National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3. Liver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 4. Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract
BACKGROUND: The present study was aimed to determine the effect of Germinated Barley Foodstuff (GBF) administration on serum C-reactive protein (CRP) levels and clinical signs in patients with Ulcerative Colitis (UC). METHODS:Forty-six patients were randomly allocated into GBF group and control group. Subjects in control group received only conventional drug therapy, while the GBF group received 30g GBF per day (3 times a day) by oral administration during 2 month along with routine medications. RESULTS: The mean serum CRP in the GBF group decreased significantly (P=0.017) compared with the baseline. Although the frequency of clinical signs including the number of episodes diarrhea, degree of visible blood in stool, degree of abdominal pain or cramping, nausea, vomiting, and anorexia decreased in the GBF group but it was statistically significant only in the case of abdominal pain and cramping. However, this reduction was only significant in the case of abdominal pain and cramping (P=0.016) CONCLUSIONS: The consumption of GBF along with the current medication may be efficient in attenuating the inflammation and clinical signs of UC patients.
RCT Entities:
BACKGROUND: The present study was aimed to determine the effect of Germinated Barley Foodstuff (GBF) administration on serum C-reactive protein (CRP) levels and clinical signs in patients with Ulcerative Colitis (UC). METHODS: Forty-six patients were randomly allocated into GBF group and control group. Subjects in control group received only conventional drug therapy, while the GBF group received 30g GBF per day (3 times a day) by oral administration during 2 month along with routine medications. RESULTS: The mean serum CRP in the GBF group decreased significantly (P=0.017) compared with the baseline. Although the frequency of clinical signs including the number of episodes diarrhea, degree of visible blood in stool, degree of abdominal pain or cramping, nausea, vomiting, and anorexia decreased in the GBF group but it was statistically significant only in the case of abdominal pain and cramping. However, this reduction was only significant in the case of abdominal pain and cramping (P=0.016) CONCLUSIONS: The consumption of GBF along with the current medication may be efficient in attenuating the inflammation and clinical signs of UC patients.
Authors: Craig A Solem; Edward V Loftus; William J Tremaine; William S Harmsen; Alan R Zinsmeister; William J Sandborn Journal: Inflamm Bowel Dis Date: 2005-08 Impact factor: 5.325
Authors: K Mitsuyama; T Saiki; O Kanauchi; T Iwanaga; N Tomiyasu; T Nishiyama; H Tateishi; A Shirachi; M Ide; A Suzuki; K Noguchi; H Ikeda; A Toyonaga; M Sata Journal: Aliment Pharmacol Ther Date: 1998-12 Impact factor: 8.171